Migfilin Antibody (OTI3G1) [DyLight 594]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-72691DL594
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
DyLight 594 (Excitation = 593 nm, Emission = 618 nm)
Antibody Source
Monoclonal Mouse IgG1 Clone # OTI3G1
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Recombinant protein fragment corresponding to amino acids 1-242 of human Migfilin (NP_060026) produced in E.coli.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for Migfilin Antibody (OTI3G1) [DyLight 594]
Application
Recommended Usage
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Migfilin
Alternate Names
CAL, DKFZp434G171, FBLP-1FBLP1CSX-associated LIM, filamin binding LIM protein 1, filamin-binding LIM protein 1, filamin-binding LIM protein-1, MIG2-interacting protein, MIGFILIN, mitogen-inducible 2 interacting protein, Mitogen-inducible 2-interacting protein
Gene Symbol
FBLIM1
Additional Migfilin Products
Product Documents for Migfilin Antibody (OTI3G1) [DyLight 594]
Product Specific Notices for Migfilin Antibody (OTI3G1) [DyLight 594]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...